GHK-Cu is a small copper-binding peptide made of three amino acids — glycine, histidine, and lysine — naturally present in human plasma, saliva, and urine. Levels of this tripeptide decline steadily with age, and that observation drove decades of research into what it does when restored. The copper complex form, GHK-Cu, is the version most studied for skin and tissue applications.
The peptide's appeal comes from its breadth. It appears to stimulate collagen and glycosaminoglycan production, support new blood vessel formation, modulate inflammation, and promote wound healing — a combination that's made it a staple ingredient in topical anti-aging formulations and a growing subject of interest in tissue repair research. Newer work is also exploring its effects beyond the skin, including in the gut lining and in soft tissue implant settings.
What makes GHK-Cu distinctive is the role of copper. The peptide acts partly as a delivery vehicle for copper ions, which are cofactors for enzymes involved in collagen cross-linking and antioxidant defense. The combination — the tripeptide framework plus the bound copper — produces effects that neither component achieves alone.
GHK-Cu and Skin Aging
Skin is where GHK-Cu has been studied most extensively. A 2025 review focused on its role as a topical anti-wrinkle peptide concluded that cellular studies consistently support its ability to stimulate collagen production, enhance glycosaminoglycan synthesis, and promote tissue regeneration (3). The peptide also appears to support angiogenesis — the formation of new blood vessels — and nerve outgrowth, both of which contribute to skin that looks and behaves younger.
The collagen story is particularly interesting because GHK-Cu seems to work synergistically with other skin care ingredients. A 2023 study testing GHK-Cu alongside hyaluronic acid found that at a 1:9 ratio with low-molecular-weight hyaluronic acid, the combination boosted collagen IV synthesis by 25-fold in fibroblast tests and roughly 2-fold in ex vivo skin samples (5). Collagen IV is the structural protein at the dermal-epidermal junction — the layer that keeps skin firmly anchored and resilient — so improvements there matter for skin tone and elasticity.
The practical challenge with topical GHK-Cu is permeation. The peptide is hydrophilic and chemically unstable, which limits how much actually reaches the deeper skin layers where it can work. Reviews have examined strategies to address this, including liposomal encapsulation, palmitoylated derivatives like Pal-GHK, microneedle pretreatment, and cell-penetrating peptide carriers (3, 4). Liposomal delivery in particular appears promising, though the methods to fully characterize its transport are still being developed.
GHK-Cu and Inflammation
Beyond cosmetic applications, GHK-Cu has shown anti-inflammatory and antioxidant effects across several research settings. A 2025 study developed an injectable hydroxyapatite microsphere filler loaded with GHK-Cu and tested it in inflammation models (2). The formulation released the peptide steadily over seven days and reduced inflammatory cytokine levels, lowered reactive oxygen species, and increased superoxide dismutase activity — a key antioxidant enzyme that neutralizes harmful free radicals. Tissue analysis showed significant collagen deposition in treated areas, suggesting the peptide simultaneously calms inflammation and supports rebuilding.
This dual action — quieting inflammatory signaling while promoting structural repair — is what makes GHK-Cu interesting outside of skin care. The same properties that help aging skin recover also appear to help damaged tissue under inflammatory stress, which is why researchers are now testing it in contexts like soft tissue implants where chronic low-grade inflammation otherwise interferes with healing.
GHK-Cu and Gut Healing
One of the more unexpected research directions for GHK-Cu involves the gut lining. A 2025 study examined the peptide in a colitis model and found it reduced disease activity scores, suppressed inflammatory cytokines including TNF-α, IL-6, and IL-1β, increased goblet cell numbers, and promoted mucosal repair (1). Goblet cells produce the protective mucus layer that lines the colon, and their loss is a hallmark of inflammatory bowel disease.
The mechanism appears to involve the SIRT1/STAT3 signaling pathway. SIRT1 is a longevity-associated enzyme that GHK-Cu seems to activate, while STAT3 is an inflammation-driving transcription factor that the peptide suppresses. When researchers silenced STAT3 directly, GHK-Cu's effects on tight junction proteins like ZO-1 and Occludin — the molecular zippers that hold gut lining cells together — disappeared, confirming that pathway as central to its action (1). The peptide also appeared to reduce Th17 immune cells, which drive chronic intestinal inflammation. These findings open a new line of investigation for GHK-Cu well beyond the skin applications it's traditionally associated with.